Answers are grounded in this paper and cite their sources.
Purpose: To assess the efficacy and safety outcomes of case reports of danaparoid anticoagulation in critically ill ICU patients suffering from HIT who require CRRT. Method: A retrospective analysis of 103 cases.Results: Based on clinical signs, pre-treatment 4T scores and serological testing, HIT was reasonably 'confirmed' in 67.0% of the cases and 'suspected' in the remainder.The patients, with HIT and ARF received the danaparoid treatment regimen for CRRT for 1-39 (median 7) days.Dose adaptation was necessary in 40.2% of the patients to overcome thrombosis or bleeding (risk).Satisfactory CRRT anticoagulation was provided for 93.6% of 94 cases with information, 53.9% of the patients survived.The hospital mortality of 46.1% was mainly attributed to concomitant morbidity, but 5 deaths were related to thrombosis (n=2) or bleeding (n=3).Maintenance plasma anti-Xa activity correlated poorly with bleeding or thrombotic complications but positively with the minor bleeding frequency, hence advice to restrict the upper limit to 0.8 U/mL or preferably to use evidence of bleeding and systemic thrombosis/ circuit clotting to judge the need for dose adaptation.The benefit (no thrombosis)/harm (bleeding induction) ratio and combined inefficacy and major haemorrhagic frequency were 10.5 and 16.6% respectively, showing a generally favourable response to danaparoid. Conclusions:This case report analysis shows that danaparoid, despite its renal elimination, long half-life and lack of antidote, appears to provide efficacious and safe anticoagulation for the majority of critically ill patients with HIT and ARF who are undergoing CRRT.
No takes yet. Share an insight, caveat, or question.
Wester JPJ (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: